Principal Investigator - Dr. Scott Dryden-Peterson MD, MSc
Thabatse is a prospective cohort study which aims to evaluate the risk factors for cancer and describe the response to treatment for patients who are HIV positive and not on Antiretroviral Therapy (ART) and those on ART.
The primary aims are to evaluate the important risk factors for cancer in Botswana (including HIV) and describe the response to treatment for patients without HIV, with HIV but not yet on HAART, and those with HIV and on HAART.
The specific aims are to:
- Describe patient characteristics (including cancer stage at diagnosis and comorbidities), treatment provided, clinical response, and 12-month outcome (remission and survival) for the most common cancers.
- Determine prevalence of HIV infection and median CD4 cell count for patients presenting for oncologic care.
- Compare the rate of treatment-limiting toxicity (hepatitis, neutropenia, anemia, renal failure, and infection) and CD4 trajectory between HIV-infected patients on HAART with those not yet on HAART. Explore relationship between HAART and clinical response to oncologic treatment.
- Describe trends in age-standardized incidence between 1999 and 2009 for leading AIDS-defining cancers (Kaposi’s Sarcoma, B-Cell NHL, invasive cervical carcinoma) and non-AIDS defining cancers (breast, esophagus, head and neck, prostate
Observational cohort study and registry analysis.
Up to 900 patients annually for a total of 6000 participants. Participants will be adult patients, both HIV-infected and HIV-uninfected, with cancer in Botswana.
Study Duration: 5 years
Sponsor: Nation Institute of Health (NIH)